<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906201</url>
  </required_header>
  <id_info>
    <org_study_id>125/18</org_study_id>
    <nct_id>NCT03906201</nct_id>
  </id_info>
  <brief_title>Effect of Phytoecdysterone Administration in Subjects With Prediabetes</brief_title>
  <official_title>Effect of Phytoecdysterone Administration on Cytotoxicity, Genotoxicity and Metabolic Control in Subjects With Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prediabetes is the term used for people whose glucose levels do not meet the criteria for
      diabetes but are too high to be considered normal. This is defined by the presence of blood
      glucose between 100-125 mg / dL, values per glucose tolerance curve of 140-199mg / dL and/or
      HbA1c 5.7-6.4%. Prediabetes should not be considered as a clinical entity in itself, but as a
      risk factor for diabetes and cardiovascular disease (CVD). Prediabetes is associated with
      obesity (especially abdominal or visceral obesity), dyslipidemia with elevated triglycerides
      and/or low HDL cholesterol, and hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with a diagnosis of prediabetes are included according to the criteria of the
      American Diabetes Association in its version 2019, between 30 and 60 years old residents of
      the city of Guadalajara, Jalisco, Mexico who come to clinical nutrition consultation in the
      University Hospital Fray Antonio Alcalde from the city of Guadalajara, Jalisco, Mexico.

      The study design is a randomized, randomized clinical trial with a control group in two
      groups: an intervention group with ecdysterone 300mg every 24 hours for 12 weeks
      (approximately 90 days) and an approved placebo control group (magnesia stearate) ) at 300mg
      every 24 hours for 12 weeks (approximately 90 days).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>cohort populations with diagnostic metabolic syndrome treatment base with ecdysterone for 90 days</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
    <masking_description>Randomized double-blind clinical trial plus control group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the number of micronuclei after 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>The number of micronuclei will be evaluated at baseline and day 90 with Schmidt technique by giemsa/wright and the entered values reflect the number of micronuceli at day 90</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in fasting glucose levels after 90 days of intervention with betaecdysterone and placebo</measure>
    <time_frame>90 days</time_frame>
    <description>The fasting glucose levels will be evaluated at baseline and day 90 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at day 90</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in glycosylated hemoglobin (A1C) after 90 days of intervention with betaecdysterone and placebo</measure>
    <time_frame>90 days</time_frame>
    <description>Glycosylated hemoglobin will be evaluated at baseline and day 90 by high pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at day 90</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>90 days</time_frame>
    <description>The body weight will be measured at baseline, day 30, day 60 and day 90 with a bioimpedance balance and the entered values reflect the body weight at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>90 days</time_frame>
    <description>Body Mass Index will be calculated at baseline, day 30, day 60 and day 90 with the Quetelet index formula and the entered values reflect the body mass index at day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>90 days</time_frame>
    <description>Waist circumference will be evaluated at baseline and at day 90 with a flexible tape</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>90 days</time_frame>
    <description>Total cholesterol levels will be evaluated at baseline and day 90 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides levels</measure>
    <time_frame>90 days</time_frame>
    <description>Triglycerides levels will be evaluated at baseline and day 90 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein (c-HDL) levels</measure>
    <time_frame>90 days</time_frame>
    <description>c-HDL levels will be evaluated at baseline and day 90 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoproteins (c-LDL) levels</measure>
    <time_frame>90 days</time_frame>
    <description>c-LDL levels will be evaluated at baseline and day 90 with enzymatic/colorimetric techniques and the entered values reflect the c-LDL level at day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine levels</measure>
    <time_frame>90 days</time_frame>
    <description>Creatinine levels will be evaluated at baseline and day 90 with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase (ALT) levels</measure>
    <time_frame>90 days</time_frame>
    <description>ALT levels will be evaluated at baseline and day 90 with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase (AST) levels</measure>
    <time_frame>90 days</time_frame>
    <description>AST levels will be evaluated at baseline and day 90 enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>90 days</time_frame>
    <description>Blood pressure will be measured at baseline and day 90 with a digital sphygmomanometer and the entered values reflect the blood pressure at day 90</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 with placebo treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ecdysterone Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 whit ecdysterone treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ecdysterone</intervention_name>
    <description>Food supplement of plant origin with pronounced biological activity and potentially hypoglycaemic</description>
    <arm_group_label>Ecdysterone Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>no pharmacologic effect</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>magnesia stearate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. - Fasting Plasma Glucose between 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L)

          2. - Oral Glucose Tolerance Test 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L)

          3. - A1C 5.7-6.4% (39-47 mmol/mol).

          4. - Body Mass Index &gt;25 kg/m2 or &gt;23 kg/m2

          5. - Adults who have one or more of the following risk factors:

               -  First-degree relative with diabetes

               -  High-risk race/ethnicity

               -  History of CVD

          6. - Blood Pressure &lt;140/90 mmHg without therapy for hypertension

          7. - HDL cholesterol level &lt;0.35 mg/dL (0.90 mmol/L) and/or a triglyceride level &gt;0.250
             mg/dL (2.82 mmol/L)

        Exclusion Criteria:

        1.- Pregnant women or lactic period 2- Patients with some other chronic degenerative
        disease like diabetes mellitus 2 with pharmacologic treatment.

        3.- Hypertension 4.- Cancer, 5.- Hyperthyroidism 6.- Hypothyroidism 7.- Immunologic disease
        8.- Kidney disease 9.- Hepatic disease 10.- Cardiovascular disease 11- Abaqus activity
        12.-Alcoholic activity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ANA FLETES</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ANA FLETES</last_name>
    <phone>011521-3310585200</phone>
    <email>anna.fletes@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ana Fletes</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANA FLETES</last_name>
      <phone>3310585200</phone>
      <phone_ext>34097/34098</phone_ext>
      <email>anna.fletes@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://fmdiabetes.org/wp-content/uploads/2019/01/ada-2019.pdf</url>
    <description>The journal of clinical and applied research and education. Diabetes Care. American Diabetes Association. Standards of Medical Care in Diabetes-2019.</description>
  </link>
  <reference>
    <citation>Álvarez-Gasca Ma, Hernández-Pozo MR, Jiménez-Martínez M, Durán-Díaz A. Estilo de vida y presencia de síndrome metabólico en estudiantes universitarios. Diferencias por sexo. Rev de psicología. 2014; 32(1):121-138</citation>
  </reference>
  <reference>
    <citation>Andreassi MG, Barale R, Iozzo P, Picano E. The association of micronucleus frequency with obesity, diabetes and cardiovascular disease. Mutagenesis. 2011 Jan;26(1):77-83. doi: 10.1093/mutage/geq077. Review.</citation>
    <PMID>21164186</PMID>
  </reference>
  <reference>
    <citation>•Aparicio MR, Estrada LA, Fernández C, Hernández RM, Ruiz M, Ramos D, et al. Manual de antropometría. Instituto nacional de ciencias médicas y nutrición salvador zubirán: 2014 citar en:http://www.facmed.unam.mx/deptos/salud/censenanza/spi/unidad2/antropometria_manualinnsz.pdf</citation>
  </reference>
  <reference>
    <citation>Berti C, Riso P, Monti LD, Porrini M. In vitro starch digestibility and in vivo glucose response of gluten-free foods and their gluten counterparts. Eur J Nutr. 2004 Aug;43(4):198-204. Epub 2004 Jan 6.</citation>
    <PMID>15309439</PMID>
  </reference>
  <reference>
    <citation>Graf BL, Poulev A, Kuhn P, Grace MH, Lila MA, Raskin I. Quinoa seeds leach phytoecdysteroids and other compounds with anti-diabetic properties. Food Chem. 2014 Nov 15;163:178-85. doi: 10.1016/j.foodchem.2014.04.088. Epub 2014 May 4.</citation>
    <PMID>24912714</PMID>
  </reference>
  <reference>
    <citation>FAO, 2013. Food and agriculture organization of the united nations rome. Http://www.fao.org/docrep/018/i3300e/i3300e00.pdf</citation>
  </reference>
  <reference>
    <citation>FAO. Food and agriculture organization of the united nations 2011. La quinua: cultivo milenario para contribuir a la seguridad alimentaria mundial. Http://www.fao.org/docrep/017/aq287s/aq287s.pdf</citation>
  </reference>
  <reference>
    <citation>Figuerola F, Muñoz O, Estévez AM. La linaza como fuente de compuestos bioactivos para la elaboración de alimentos. Agro sur. 2008; 36(2): 49-58. Doi:10.4206/agrosur.2008.v36n2-01</citation>
  </reference>
  <reference>
    <citation>Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu l, et al. Encuesta nacional de salud y nutrición 2012. Resultados nacionales. Cuernavaca, méxico: instituto nacional de salud pública (mx), 2012</citation>
  </reference>
  <reference>
    <citation>Harishankar MK, Logeshwaran S, Sujeevan S, Aruljothi KN, Dannie MA, Devi A. Genotoxicity evaluation of metformin and glimepiride by micronucleus assay in exfoliated urothelial cells of type 2 diabetes mellitus patients. Food Chem Toxicol. 2015 Sep;83:146-50. doi: 10.1016/j.fct.2015.06.013. Epub 2015 Jun 24.</citation>
    <PMID>26115598</PMID>
  </reference>
  <reference>
    <citation>Karaman A, Aydın H, Geçkinli B, Çetinkaya A, Karaman S. DNA damage is increased in lymphocytes of patients with metabolic syndrome. Mutat Res Genet Toxicol Environ Mutagen. 2015 Apr;782:30-5. doi: 10.1016/j.mrgentox.2015.03.009. Epub 2015 Mar 13.</citation>
    <PMID>25868129</PMID>
  </reference>
  <reference>
    <citation>León-Muñoz LM, Guallar-Castillón P, López García E, Banegas JR, Gutiérrez-Fisac JL, Rodríguez-Artalejo F. Relationship of BMI, waist circumference, and weight change with use of health services by older adults. Obes Res. 2005 Aug;13(8):1398-404.</citation>
    <PMID>16129722</PMID>
  </reference>
  <reference>
    <citation>Lizarzaburu-Robles JC. Síndrome metabólico: metabolicsyndrome: concept and practical application. An facmed. 2013;74(4):315-320.</citation>
  </reference>
  <reference>
    <citation>Kaufer-Horwitz M, Toussaint G. Indicadores antropométricos para evaluar sobrepeso y obesidad en pediatría. Bol. Med. Hosp. Infant. Mex; 2008;65(6): 502-518.</citation>
  </reference>
  <reference>
    <citation>Moreno-Altamirano l, García-García JJ, Soto-Estrada G, Capraro S, Limón-Cruz D. Epidemiología y determinantes sociales asociados a la obesidad y la diabetes tipo 2 en méxico. Revmedhosp gen méx. 2014; 77(3):86-95.</citation>
  </reference>
  <reference>
    <citation>Morris D, Vaisey-Genserb. Availability and labeling of flaxseedfood, products and supplements. In: thompson, l. U.; cunnane s. C. Flaxseed in human nutrition. 2003. 2nd edn., champaign, illinois. Aocs press. Pp. 404-422.</citation>
  </reference>
  <reference>
    <citation>Murakami A, Ashida H, TeraoJj. Multitargeted cancer prevention by quercetin. Cancer lett. 2008;269(2):315-25. Doi: 10.1016/j.canlet.2008.03.046. Norma oficial mexicana nom-037-ssa2-2012, para la prevención, tratamiento y control de las dislipidemias. Citar en: http://www.dof.gob.mx/nota_detalle.php?codigo=5259329&amp;fecha=13/07/2012</citation>
  </reference>
  <reference>
    <citation>Ojeda-Lavin A. Proyecciones de la población 2010-2050. Consejo nacional de población méxico. 2014.http://www.conapo.gob.mx/es/conapo/proyecciones.</citation>
  </reference>
  <reference>
    <citation>Omsa. Datos y cifras. 10 datos sobre la obesidad. 2015. Disponible en: http://www.who.int/features/factfiles/obesity/facts/es/index1.html</citation>
  </reference>
  <reference>
    <citation>Cuevas ZO, Sangronis E. [Characterization of flaxseed (Linum usitatissimum L.) grown in Venezuela]. Arch Latinoam Nutr. 2012 Jun;62(2):192-200. Spanish.</citation>
    <PMID>23610908</PMID>
  </reference>
  <reference>
    <citation>Peñarrieta JM, Alvarado JA, Akesson B, Bergenståhl B. Total antioxidant capacity and content of flavonoids and other phenolic compounds in canihua (Chenopodium pallidicaule): an Andean pseudocereal. Mol Nutr Food Res. 2008 Jun;52(6):708-17. doi: 10.1002/mnfr.200700189.</citation>
    <PMID>18537130</PMID>
  </reference>
  <reference>
    <citation>Rajesha J, Murthy KN, Kumar MK, Madhusudhan B, Ravishankar GA. Antioxidant potentials of flaxseed by in vivo model. J Agric Food Chem. 2006 May 31;54(11):3794-9.</citation>
    <PMID>16719498</PMID>
  </reference>
  <reference>
    <citation>Ramcharitar A, Badrie N, Mattfeldtbeman M, Matsuo H, Ridley C. Consumeracceptability of muffinswithflaxseed (linumusitatissimum). J. Foodsci 2005;70: 504-507.</citation>
  </reference>
  <reference>
    <citation>Ranilla LG, Apostolidis E, Genovese MI, Lajolo FM, Shetty K. Evaluation of indigenous grains from the Peruvian Andean region for antidiabetes and antihypertension potential using in vitro methods. J Med Food. 2009 Aug;12(4):704-13. doi: 10.1089/jmf.2008.0122.</citation>
    <PMID>19735168</PMID>
  </reference>
  <reference>
    <citation>Repo-Carrasco-Valencia R, Hellströmb JK, Juha-Matti P, Mattila PH. Flavonoids and other phenolic compounds in andean indigenous grains: quinoa (chenopodium quinoa), kañiwa (chenopodium pallidicaule) and kiwicha (amaranthus caudatus). Food chemistry. 2010; 120(1):128-133.</citation>
  </reference>
  <reference>
    <citation>Shahidi F, Kim SK. Quality management of marine nutraceuticals. In: ho c-t, zheng qy, editors. Quality management of nutraceuticals. Acs symposium series 803. Washington, d.c.: american chemical society. 2002.p. 76-87.</citation>
  </reference>
  <reference>
    <citation>Spedding G, Ratty A, Middleton E Jr. Inhibition of reverse transcriptases by flavonoids. Antiviral Res. 1989 Sep;12(2):99-110.</citation>
    <PMID>2480745</PMID>
  </reference>
  <reference>
    <citation>Stewart LK, Soileau JL, Ribnicky D, Wang ZQ, Raskin I, Poulev A, Majewski M, Cefalu WT, Gettys TW. Quercetin transiently increases energy expenditure but persistently decreases circulating markers of inflammation in C57BL/6J mice fed a high-fat diet. Metabolism. 2008 Jul;57(7 Suppl 1):S39-46. doi: 10.1016/j.metabol.2008.03.003.</citation>
    <PMID>18555853</PMID>
  </reference>
  <reference>
    <citation>Torres-Bugarín O, Ramos-Ibarra ML. Utilidad de la prueba de micronúcleos y anormalidades nucleares en células exfoliadas de mucosa oral en la evaluación de daño genotóxico y citotóxico. Int. J. Morphol. 2013. 31(2):650-657.</citation>
  </reference>
  <reference>
    <citation>Torres-Bugarín O, Zavala-cerna MG, Macriz-Romero N, Flores-García A, Ramos-Ibarra ML. Procedimientos básicos de la prueba de micronúcleos y anormalidades nucleares en células exfoliadas de mucosa oral. El residente. 2013; (8):4-11.</citation>
  </reference>
  <reference>
    <citation>Voss S, Hesse A, Zimmermann DJ, Sauerbruch T, von Unruh GE. Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test. J Urol. 2006 May;175(5):1711-5.</citation>
    <PMID>16600737</PMID>
  </reference>
  <reference>
    <citation>Hou Y, Aboukhatwa MA, Lei DL, Manaye K, Khan I, Luo Y. Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacology. 2010 May;58(6):911-20. doi: 10.1016/j.neuropharm.2009.11.002. Epub 2009 Nov 14.</citation>
    <PMID>19917299</PMID>
  </reference>
  <reference>
    <citation>Zimmet P, M M Alberti KG, Serrano Ríos M. [A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results]. Rev Esp Cardiol. 2005 Dec;58(12):1371-6. Spanish. Erratum in: Rev Esp Cardiol. 2006 Feb;59(2):185.</citation>
    <PMID>16371194</PMID>
  </reference>
  <reference>
    <citation>Zong G, Demark-Wahnefried W, Wu H, Lin X. Efectos de la suplementación de semilla de linaza sobre los ácidos grasos en membranas de eritrocitos y múltiples marcadores cardiometabolico en chinos con factores de riesgo para síndrome metabólico. Eur j nutr 2013; 52: 1547-1551.</citation>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Ana Lilia Fletes Rayas</investigator_full_name>
    <investigator_title>Reseach Professor Associated</investigator_title>
  </responsible_party>
  <keyword>PreDiabetes</keyword>
  <keyword>Ecdysterone</keyword>
  <keyword>Genotoxicity</keyword>
  <keyword>Citotoxicity</keyword>
  <keyword>Micronuclei</keyword>
  <keyword>Glycemic Control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>THE RESULTS GENERATED AND THE PERSONAL DATA OF THE PARTICIPANTS ARE ON THE CONSENT OF THE SUBJECT OF STUDY AND OF THE PRINCIPAL INVESTIGATOR. THEY ARE EXTRICTLY CONFIDENTIAL AND WILL ONLY BE USED BY HOSPITAL DOCTORS</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

